Consequently, combination therapy currently involves the administration of one cholinergic drug (donepezil, galantamine or rivastigmine) and one glutamatergic drug (memantine). There have been no ...
Our NICE Advice service will guide you there. Get reliable scientific advice and NHS insights, direct from NICE. We support companies seeking nationwide adoption of the best treatments and care. Our ...
New York-based Forest Laboratories is testing Namenda (memantine), an Alzheimer's drug and N-methyl D-aspartate receptor (NMDA) receptor modulator, in a phase 2 trial in autism patients.